NasdaqGS:ZVRAPharmaceuticals
Zevra Therapeutics (ZVRA) Following EMA Setback Is The Sell Off A Valuation Gap
Zevra Therapeutics (ZVRA) is back in focus after the European Medicines Agency’s CHMP issued a negative opinion on arimoclomol for Niemann Pick disease type C, prompting a planned re examination and a sharp share price reaction.
See our latest analysis for Zevra Therapeutics.
The CHMP setback has hit sentiment hard in the short term, with Zevra Therapeutics’ share price down 23.92% over one day and 27.18% over 30 days. However, its year to date share price return of 14.21% and three year...